Core Insights - Insilico Medicine has initiated a global multicenter clinical trial for ISM3412, a potential best-in-class MAT2A inhibitor, targeting locally advanced and metastatic solid tumors [1] - The Phase I clinical study includes dose escalation and dose selection optimization, with the first patient dosed and dose-limiting toxicity observed in China [1] - ISM3412 is designed to selectively kill MTAP-deficient cancer cells while protecting healthy cells, addressing a common mutation in various solid tumors [1] Company Developments - Insilico Medicine's CEO highlighted the first patient dosing as a significant milestone in transitioning from preclinical research to human validation [1] - The company utilizes its proprietary Chemistry42 platform to develop ISM3412, which has high oral bioavailability and selectivity [1] - The average time from project initiation to clinical candidate nomination for Insilico's self-developed projects is significantly reduced to 12-18 months, compared to the traditional 2.5-4 years [2] Industry Impact - The innovative approach of using AI in drug development is setting a benchmark for efficiency in the pharmaceutical industry [2] - Insilico Medicine's success rate from preclinical candidate to IND-enabling stage is reported to be 100%, indicating a strong potential for future drug development [2]